Program Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review

Transcription

1 Program Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review Friday, February 15, :45 a.m. Registration, Breakfast and Exhibits 7:30 a.m. Welcome and Introductions SESSION 1: MYELOMA 7:45 a.m. Session 1-2 Pre-Test 8:00 a.m. Management of Newly Diagnosed Multiple Myeloma Including Stem Cell Transplantation Sikander Ailawadhi, M.D. 8:30 a.m. Benefits of Maintenance Therapy and the Treatment of the First Relapse: A Second Chance 9:00 a.m. Subsequent Relapse Keith Stewart, M.B., Ch.B 9:30 a.m. Question and Answer Session Sikander Ailawadhi, M.D.; ; Keith Stewart, M.B., Ch.B 9:45 a.m. Refreshment Break and Exhibits SESSION 2: MYELOID DISORDERS 10:00 a.m. MDS / MPN Overlap Syndromes Mrinal S. Patnaik, M.B.B.S. 10:30 a.m. Allogeneic BMT: Who to Refer and Donor Selection Lisa Z. Sproat, M.D., M.S.W. 11:00 a.m. Update on Myelodysplastic Syndromes Guillermo Garcia-Manero, M.D. 11:30 a.m. Question and Answer Session Guillermo Garcia-Manero, M.D.; Mrinal S. Patnaik, M.B.B.S. Lisa Z. Sproat, M.D., M.S.W.

2 Friday, February 15, 2019 (continued) 11:45 a.m. Session 1-2 Post-Test Noon Lunch (provided) SESSION 3: NON-HODGKINS LYMPHOMA 1:00 p.m. Session 3-4 Pre-Test 1:15 p.m. Primary Central Nervous System Lymphoma (PCNSL): Update 2019 Brian Patrick O Neill, M.D. 1:45 p.m. Update on Diffuse Large B Cell Lymphoma (DLBCL) Therapy Allison C. Rosenthal, D.O. 2:15 p.m. Mantle Cell Lymphoma Update Thomas E. Witzig, M.D. 2:45 p.m. Question and Answer Session Brian Patrick O Neill, M.D.; Allison C. Rosenthal, D.O.; Thomas E. Witzig, M.D. 3:00 p.m. Refreshment Break and Exhibits SESSION 4: BENIGN HEMATOLOGY / CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 3:15 p.m. Thromboembolism Management and Thrombocytopenia Leslie J. Padrnos, M.D. 3:45 p.m. Direct Oral Anticoagulants: Guidelines for Clinical Practice Prakash Vishnu, M.B.B.S. 4:15 p.m. How Do I Assess My CLL Patients Risk for Progression and What is My Best Choice for Upfront Therapy in 2019? Neil E. Kay, M.D. 4:45 p.m. Question and Answer Session Neil E. Kay, M.D.; Leslie J. Padrnos, M.D.; Prakash Vishnu, M.B.B.S. 5:00 p.m. Session 3-4 Post-Test 5:15 p.m. Adjourn 5:30 p.m. Welcome Reception

3 Saturday, February 16, :45 a.m. Breakfast and Exhibits 7:30 a.m. Announcements SESSION 5: CAR T-CELL THERAPY (PART I) 7:45 a.m. Session 5-6 Pre-Test 8:00 a.m. From Model T to Tesla: A Brief History of CARs for Lymphoma Jeremy S. Abramson, M.D. 9:00 a.m. Updates on CAR-T Cell Therapy in Lymphoma Allison C. Rosenthal, D.O. 9:30 a.m. Refreshment Break and Exhibits SESSION 6: CAR T-CELL THERAPY (PART II) 9:45 a.m. CARs and More: How Fast Are They Moving? Januario Castro, M.D. 10:15 a.m. Myeloma CAR-T Therapy Yi Lin, M.D., Ph.D. 10:45 a.m. Panel Discussion: The Future of CAR-T Cells Jeremy S. Abramson, M.D.; Januario Castro, M.D.; Yi Lin, M.D., Ph.D.; Allison C. Rosenthal, D.O. 11:30 a.m. Session 5-6 Post-Test 11:45 a.m. Lunch (provided) SESSION 7: SOLID TUMORS (PART I) 12:45 p.m. Session 7-8 Pre-Test 1:00 p.m. Update on Diagnosis and Treatment of Glioma Alyx Porter, M.D. 1:30 p.m. Neoadjuvant and Adjuvant Therapy for Lung Cancer Patrick Forde, M.B.B.Ch.

4 Saturday, February 16, 2019 (continued) 2:00 p.m. Update in the Management of Metastatic Lung Cancer Harshita R. Paripati, M.D. 2:30 p.m. Question and Answer Session Patrick Forde, M.B.B.Ch.; Harshita R. Paripati, M.D.; Alyx Porter, M.D. 2:45 p.m. Refreshment Break and Exhibits SESSION 8: SOLID TUMORS (PART II) 3:00 p.m. Integrating New Therapeutics into Bladder Cancer Treatment Jonathan E. Rosenberg, M.D. 3:30 p.m. Sequencing Therapies in Metastatic Kidney Cancer Thai H. Ho, M.D., Ph.D. 4:00 p.m. Cardio-Oncology: A Multidisciplinary Approach to Managing Cardiovascular Complications in Cancer Patients Farouk Mookadam, M.B., B.Ch. 4:30 p.m. Incorporating Cancer Survivorship Care Plans into a Busy Clinical Practice: Meeting Clinical Guidelines and Addressing Patient Need Noel Arring, D.N.P., Ph.D., R.N., O.C.N. 4:45 p.m. Question and Answer Session Noel Arring, D.N.P., Ph.D., R.N., O.C.N.; Thai H. Ho, M.D., Ph.D.; Farouk Mookadam, M.B., B.Ch.; Jonathan E. Rosenberg, M.D. 5:00 p.m. Session 7-8 Post-Test 5:15 p.m. Adjourn

5 Sunday, February 17, :45 a.m. Breakfast and Exhibits 7:30 a.m. Announcements SESSION 9: SOLID TUMORS (PART III) 7:45 a.m. Session 9-10 Pre-Test 8:00 a.m. Novel Approaches to HER2+ and Triple Negative Breast Cancers Edith A. Perez, M.D. 8:30 a.m. Adjuvant Management of Hormone Receptor Positive Breast Cancer Donald W. Northfelt, M.D., F.A.C.P. 9:00 a.m. Familial Cancer Syndromes: An Under-Diagnosed Problem Niloy (Jewel) Samadder, M.D. 9:30 a.m. Question and Answer Session Donald W. Northfelt, M.D., F.A.C.P.; Edith A. Perez, M.D.; Niloy (Jewel) Samadder, M.D. 9:45 a.m. Refreshment Break and Exhibits SESSION 10: SOLID TUMORS (PART IV) 10:00 a.m. Hepatobiliary Cancer Mitesh J. Borad, M.D. 10:30 a.m. Advances in the Diagnosis and Management of Neuroendocrine Tumors Thorvardur R. Halfdanarson, M.D. 11:00 a.m. Clinical Updates in the Treatment of Advanced Colorectal and Gastro-Esophageal Cancers Tanios S. Bekaii-Saab, M.D., F.A.C.P. 11:30 a.m. Question and Answer Session Tanios S. Bekaii-Saab, M.D., F.A.C.P.; Mitesh J. Borad, M.D.; Thorvardur R. Halfdanarson, M.D. 11:45 a.m. Session 9-10 Post-Test Noon Closing Comments, Evaluation and Adjourn